Absci Corporation (ABSI)
(Delayed Data from NSDQ)
$4.58 USD
+0.13 (2.81%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $4.57 -0.01 (-0.22%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ABSI 4.58 +0.13(2.81%)
Will ABSI be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ABSI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ABSI
Absci Corporation (ABSI) Moves 16.8% Higher: Will This Strength Last?
Absci Corporation (ABSI) Surges 10.0%: Is This an Indication of Further Gains?
ABSI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Centene (CNC) Stock Outpacing Its Medical Peers This Year?
Is Absci Corporation (ABSI) Outperforming Other Medical Stocks This Year?
Absci (ABSI) Up on AstraZeneca Deal to Design New Cancer Therapy
Other News for ABSI
Moderna and OpenAI in pact to fast-track drug development
Clinical-Stage BioTech Drug Stocks Portfolio Went Down 9% Last Week
Video: Tuesday's ETF Movers: ARKG, PICK
All 7 AI Category Portfolios Continued To Decline This Week
Absci to Report Business Updates and First Quarter 2024 Financial and Operating Results on May 14, 2024